Nicole Longo Nicole is senior manager of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
Medicare Monday: New Xcenda white paper looks at four strengths of Part B
By Nicole Longo | April 30, 2018
In case you missed it, a recent white paper from Xcenda took a deeper look at how Medicare Part B reimburses for physician-administered medicines and how the program has evolved over time. The...
Read More
340B Spotlight: How much money are hospitals pocketing under 340B and what are they doing with those profits?
By Nicole Longo | March 28, 2018
The once little-known 340B drug discount program, which was designed to help low-income, uninsured or otherwise vulnerable patients access prescription medicines at safety-net facilities, is now a...
Read More
Medicare Monday: Moran finds Part B medicine prices are stable, not a key driver of Medicare costs
By Nicole Longo | March 26, 2018
Earlier this year, we examined research that shows Part B spending continues to be a small, stable share of overall Medicare spending. Today, we’re looking at the trends in Average Sales Price...
Read More
What is inter partes review and why does it matter?
By Nicole Longo | March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...
Read More
340B Spotlight: Hospital system adds voice to comments about flawed 340B program
By Nicole Longo | February 2, 2018
Each week, more and more groups are calling attention to the 340B program and its myriad problems. Here’s a quick recap of some of the latest voices out there.
Read More
Fact Check Friday: The truth about the cost of 340B to patients
By Nicole Longo | January 26, 2018
The 340B program was designed to increase access to medicines for vulnerable or uninsured patients through safety-net facilities, but all signs point to 340B doing the opposite – distorting the...
Read More
Guess what? Part B drug spending remains stable share of Medicare spending
By Nicole Longo | January 23, 2018
Did you know that if you look at medicines in the pipeline for previously unmet medical needs, many are new and exciting immunotherapy treatments that are physician administered? That means these...
Read More
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
By Nicole Longo | January 18, 2018
In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters...
Read More
Medicare Monday: Helping beneficiaries access vaccines
By Nicole Longo | December 18, 2017
Last month, we released a State of Vaccines report, as well as an update to our Medicines in Development for Vaccines report, which shared exciting information about the 264 vaccines currently in...
Read More
Medicare Monday (100)
340B Spotlight (34)
Cost & Consequence (0)
